Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1b trial of DPV-001 in combination with BMS-986178 and nivolumab in patients with advanced triple negative breast cancer

Next Previous
Trial Profile

Phase 1b trial of DPV-001 in combination with BMS-986178 and nivolumab in patients with advanced triple negative breast cancer

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 29 Sep 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BMS 986178 (Primary) ; DPV 001 (Primary) ; Nivolumab (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions; First in man; Therapeutic Use

Most Recent Events

  • 24 Sep 2020 According to an UbiVac media release, the company will start this trial with partners at three Cancer Centers in the USA
  • 15 Jun 2020 New trial record
  • 09 Jun 2020 According to an UbiVac media release, the company has entered into a clinical trial collaboration with Bristol Myers Squibb to initiate this study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top